Related Experiment Video

Updated: May 20, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

A potent lead induces apoptosis in pancreatic cancer cells

Zuojia Liu1, Dan Li, Wenjing Zhao

  • 1State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.

Plos One
|June 30, 2012
PubMed

Insights

The novel compound NSC48693 effectively inhibits pancreatic cancer cell growth by inducing apoptosis. This drug shows promise as a new treatment for pancreatic cancer, with greater efficacy against cancer cells than normal cells.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Pancreatic cancer is a lethal disease with limited treatment options.
  • Developing novel, effective anticancer drugs is a critical unmet need.

Purpose of the Study:

  • To evaluate the in vitro cytotoxic effects of NSC48693 against human pancreatic cancer cell lines.
  • To elucidate the mechanism of action of NSC48693 in inducing cancer cell death.

Main Methods:

  • In vitro assessment of NSC48693's effect on CFPAC-1, MiaPaCa-2, and BxPC-3 cell proliferation.
  • Apoptosis induction assays including Annexin V staining, chromatin staining, and colony formation assays.
  • Analysis of mitochondrial pathway involvement: cytochrome c release, mitochondrial membrane potential, reactive oxygen species generation, and caspase activation.

Main Results:

  • NSC48693 demonstrated significant inhibition of pancreatic cancer cell proliferation with IC50 values ranging from 6.2 to 20.6 µM.
  • The compound effectively induced apoptosis through the mitochondrial-mediated pathway, evidenced by caspase activation and cytochrome c release.
  • Normal human cell lines (HEK-293 and HL-7702) exhibited greater resistance to NSC48693 compared to pancreatic cancer cells.

Conclusions:

  • NSC48693 exhibits potent anticancer activity against human pancreatic cancer cells in vitro.
  • The mechanism of action involves the induction of mitochondrial-mediated apoptosis.
  • NSC48693 presents a promising therapeutic opportunity for pancreatic cancer treatment due to its selective toxicity.

More Related Videos

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing06:59

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Published on: May 12, 2023

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...